Skills this job asks for
Supply chainLeadershipLogisticsAccount management
Add your CV (free) to see which of these your CV is missing.
Sponsorship verdict
Sponsorship possible
One solid signal, not two. Worth applying, and worth asking about sponsorship early.
-
✓
Employer is on a government sponsor recordThe US Department of Labor certified 7 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first.
-
?
The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
-
?
No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area.
-
✓
Confirmed live todayWhen a source last listed this job as open.
Details and sources
- Employer is on a government sponsor record
- The US Department of Labor certified 7 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. Source: LCA disclosure data (US Department of Labor (OFLC)).
- No salary bar for this route
- H-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence. It is not legal advice and never a guarantee: the employer and the immigration authority decide. Sign in to factor in where you can already work.
About the role
Company Overview:
Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Position Overview:
Beam is looking for a highly motivated, strategic, and collaborative leader to join our growing Commercial team. The VP, Patient Operations, will shape the strategy, build and oversee the execution of patient scheduling and apheresis operations, including leading the selection and implementation of a cell therapy orchestration platform. The focus in the short- to mid-term will be on risto-cel, an ex vivo autologous hematopoietic stem cell-based gene therapy for the treatment of severe sickle cell disease (SCD). Patient Operations will be critical for the provider and patient experience and as such, this role will be a crucial member of the cross-functional team preparing for Beam’s potential first product commercialization. Additionally, this position will be a key strategic thought partner defining how to commercialize Beam’s next-generation hematology programs, which have the potential to address significantly more patients. The successful candidate will also help shape the strategy for commercial patient supply for our in vivo genetic medicines products.
Responsibilities:
• Define strategy for Patient Operations, including patient scheduling rules, manufacturing slot allocation, and exception management.
• Partner with Manufacturing, Supply Chain, Quality, Regulatory, IT and others to ensure scalable processes for patient scheduling and apheresis operations that meet both Beam’s business needs and ensure an exceptional patient and provider treatment experience.
• Provide strategic and operational leadership regarding the implementation of a cell therapy orchestration platform and integration into other systems to enable functions such as patient registration and scheduling, chain of identity / chain of custody (COI/COC) traceability, order management, inbound and outbound cell logistics etc.
• Partner with Key Account Management to define organizational needs to onboard and support apheresis operations at treatment centers.
• Build and manage teams to execute patient scheduling and apheresis operations.
Qualifications:
• BS/BA in a relevant academic field; MBA, MD, PhD, or other graduate degree strongly preferred.
• Typically 17+ years with 12+ years experience within the pharma/biotech/biopharma space in roles of progressively increasing responsibility.
• Experience in gene and/or cell therapy strongly desired, particularly in autologous cell therapy.
• Sophisticated understanding of the operational complexity and evolving scientific, clinical, regulatory, competitive, and economic trends in the cell / gene therapy industry, and able to adapt operational strategies accordingly.
• Proven track record in cross-functional leadership role or other cross-disciplinary background with successful team leadership experience required.
• Exceptional interpersonal skills and collaborative nature with strong ability to influence, motiva
Apply on employer site ↗